

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



康宁杰瑞

ALPHAMAB ONCOLOGY

ALPHAMAB ONCOLOGY

康寧傑瑞生物製藥

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9966)

**VOLUNTARY ANNOUNCEMENT
FIRST PATIENT DOSED IN A PHASE II CLINICAL STUDY OF
JSKN033 AS FIRST-LINE TREATMENT OF
ADVANCED CERVICAL CANCER**

This announcement is made by Alphamab Oncology (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders (the “**Shareholders**”) and potential investors of the Group about the latest business advancement of the Group.

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company is pleased to announce that the first patient has been dosed in a phase II clinical study of JSKN033 (a high-concentration subcutaneous co-formulation consisting of anti-human epidermal growth factor receptor 2 (“**HER2**”) bispecific antibody-drug conjugate (“**ADC(s)**”) and programmed death ligand 1 (“**PD-L1**”) immune checkpoint inhibitor) in combination with platinum-based chemotherapy with or without bevacizumab as first-line treatment of advanced cervical cancer (study number: JSKN033-202).

Cervical cancer is the most common gynecological malignancy and the fourth leading cause of cancer-related deaths among women. Patients with early-stage disease often experience recurrence or metastasis after treatment, while those with advanced disease have a five-year survival rate of less than 20%. Although immunotherapy combined with platinum-based (cisplatin or carboplatin) chemotherapy with or without bevacizumab represents the guideline-recommended first-line standard of care, tumor heterogeneity in cervical cancer still leads to suboptimal response to immuno-combination therapies in some patients, highlighting a clear unmet clinical need.

JSKN033 offers several distinctive advantages: subcutaneous injection greatly improves dosing convenience and compliance; its low hematologic toxicity makes it one of the few ADCs that can be safely combined with carboplatin, providing individualized, safer and more flexible treatment options tailored to patients with varying renal function and different physical tolerance levels. When combination with platinum drugs and bevacizumab, multiple synergistic antitumor effects are expected-targeted tumor killing, immune activation, anti-angiogenesis, and chemotherapy-prolonging disease control and improving patient survival. In early-stage clinical studies, JSKN033 monotherapy has demonstrated promising efficacy and a manageable safety profile in patients with cervical cancer who have failed standard therapies, laying a solid foundation for its further promotion to first-line combination therapy scenarios.

JSKN033-202 is an open-label, multicenter phase II clinical study designed to evaluate the safety, efficiency and pharmacokinetics/pharmacodynamics of JSKN033 in combination with platinum-based chemotherapy with or without bevacizumab as first-line treatment in patients with advanced cervical cancer. All patients will receive treatment with JSKN033 plus either cisplatin or carboplatin, with or without bevacizumab. The choice of platinum-based agent and the use of bevacizumab will be determined by the investigator based on the individual circumstances of the patients. The initiation of this study is expected to bring an efficient, safe, and convenient first-line treatment option to patients with advanced cervical cancer.

ABOUT JSKN033

JSKN033 is a global first high-concentration subcutaneous co-formulation with JSKN003, the HER2 bispecific ADC and Envafolelimab, the PD-L1 single domain antibody, developed by the Group. JSKN003 is a biparatopic HER2-targeting ADC, of which a topoisomerase I inhibitor is linked to the N glycosylation site of the antibody KN026 (a recombinant humanized anti-HER2 bispecific antibody) via the glycosite-specific conjugation. Envafolelimab is a Fc fusion protein consisting of humanized anti-PD-L1 single domain antibody and human Immunoglobulin G1 Fc fragment, which has been approved by the National Medical Products Administration of China (國家藥品監督管理局) (the “NMPA”) as the global-first subcutaneous injection PD-L1 inhibitor in November 2021.

JSKN033 combines the benefits of immunotherapy and ADCs while enhancing safety and convenience through subcutaneous administration. Currently, the phase II clinical study of JSKN033 in combination with platinum-based chemotherapy as first-line treatment for advanced cervical cancer is advancing smoothly. In addition, multiple monotherapy phase II clinical studies are also ongoing, with indications including second-line or above cervical cancer, second-line or above endometrial cancer, and HER2-mutant/expressing non-small cell lung cancer.

ABOUT THE COMPANY

The Company is a leading biopharmaceutical company in the PRC with a fully integrated proprietary technology platform in ADCs, bispecific antibodies and multi-functional protein engineering. The Company’s highly differentiated in-house pipeline consists of ADCs, monoclonal antibodies and bispecific antibodies in staggered development status in oncology, including, among others, one product approved for marketing by the NMPA and multiple products in phase III or pivotal clinical trial stages. The Company has developed various technologies and platforms of antibody-based therapies for oncology treatment and expertise in this regard. Benefitting from the proprietary protein engineering platforms and structure-guided molecular modeling expertise, the Company is able to create a new generation of multi-functional biological drug candidates that could potentially benefit patients globally.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will be able to develop and/or ultimately market JSKN033 successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By Order of the Board
Alphamab Oncology
Dr. XU Ting
Chairman and Executive Director

Hong Kong, May 13, 2026

As at the date of this announcement, the Board comprises Dr. XU Ting as the chairman of the Board and executive Director and Ms. LIU Yang as executive Director, Mr. CHO Man as non-executive Director, and Mr. WU Dong, Ms. WONG Yan Ki Angel and Dr. GAO Xiang as independent non-executive Directors.